{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T21:28:10Z","timestamp":1781386090494,"version":"3.54.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T00:00:00Z","timestamp":1566950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T00:00:00Z","timestamp":1566950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"F. Hoffmann-La Roche Ltd\/Genentech Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1038\/s41375-019-0559-9","type":"journal-article","created":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T13:05:41Z","timestamp":1566997541000},"page":"522-532","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["MRD response in relapsed\/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial"],"prefix":"10.1038","volume":"34","author":[{"given":"Christiane","family":"Pott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie H.","family":"Sehn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Belada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Gribben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Hoster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Kahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Kehden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Nicolas-Virelizier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Spielewoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guenter","family":"Fingerle-Rowson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Harbron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Mundt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Wassner-Fritsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce D.","family":"Cheson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,28]]},"reference":[{"key":"559_CR1","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2147\/CMAR.S34273","volume":"5","author":"MP Chao","year":"2013","unstructured":"Chao MP. Treatment challenges in the management of relapsed or refractory non-Hodgkin\u2019s lymphoma\u2014novel and emerging therapies. Cancer Manag Res. 2013;5:251\u201369.","journal-title":"Cancer Manag Res"},{"key":"559_CR2","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1182\/blood.V99.3.856","volume":"99","author":"A Rambaldi","year":"2002","unstructured":"Rambaldi A, Lazzari M, Manzoni C, Carlotti E, Arcaini L, Baccarani M, et al. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood. 2002;99:856\u201362.","journal-title":"Blood"},{"key":"559_CR3","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1111\/j.1365-2141.2008.07101.x","volume":"141","author":"C Hirt","year":"2008","unstructured":"Hirt C, Sch\u00fcler F, Kiefer T, Schwenke C, Haas A, Niederwieser D, et al. Rapid and sustained clearance of circulating lymphoma cells after chemotherapy plus rituximab: clinical significance of quantitative t(14;18) PCR monitoring in advanced stage follicular lymphoma patients. Br J Haematol. 2008;141:631\u201340.","journal-title":"Br J Haematol"},{"key":"559_CR4","doi-asserted-by":"publisher","first-page":"6094","DOI":"10.1200\/JCO.2009.22.6258","volume":"27","author":"L Goff","year":"2009","unstructured":"Goff L, Summers K, Iqbal S, Kuhlmann J, Kunz M, Louton T, et al. Quantitative PCR analysis for Bcl-2\/IgH in a phase III study of Yttrium-90 Ibritumomab Tiuxetan as consolidation of first remission in patients with follicular lymphoma. J Clin Oncol. 2009;27:6094\u2013100.","journal-title":"J Clin Oncol"},{"key":"559_CR5","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1200\/JCO.2008.17.1561","volume":"27","author":"H Hochster","year":"2009","unstructured":"Hochster H, Weller E, Gascoyne RD, Habermann TM, Gordon LI, Ryan T, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol. 2009;27:1607\u201314.","journal-title":"J Clin Oncol"},{"key":"559_CR6","doi-asserted-by":"publisher","first-page":"3759","DOI":"10.1182\/blood-2013-06-507319","volume":"122","author":"M Ladetto","year":"2013","unstructured":"Ladetto M, Lobetti-Bodoni C, Mantoan B, Ceccarelli M, Boccomini C, Genuardi E, et al. Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. Blood. 2013;122:3759\u201366.","journal-title":"Blood"},{"key":"559_CR7","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1177\/2040620713480522","volume":"4","author":"C Lobetti-Bodoni","year":"2013","unstructured":"Lobetti-Bodoni C, Mantoan B, Monitillo L, Genuardi E, Drandi D, Barbero D, et al. Clinical implications and prognostic role of minimal residual disease detection in follicular lymphoma. Ther Adv Hematol. 2013;4:189\u201398.","journal-title":"Ther Adv Hematol"},{"key":"559_CR8","doi-asserted-by":"publisher","first-page":"6398","DOI":"10.1158\/1078-0432.CCR-14-0407","volume":"20","author":"S Galimberti","year":"2014","unstructured":"Galimberti S, Luminari S, Ciabatti E, Grassi S, Guerini F, Dondi A, et al. Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial. Clin Cancer Res. 2014;20:6398\u2013405.","journal-title":"Clin Cancer Res"},{"key":"559_CR9","doi-asserted-by":"publisher","first-page":"e2017010","DOI":"10.4084\/mjhid.2017.010","volume":"9","author":"G Gritti","year":"2017","unstructured":"Gritti G, Pavoni C, Rambaldi A. Is there a role for minimal residual disease monitoring in follicular lymphoma in the chemo-immunotherapy era? Mediterr J Hematol Infect Dis. 2017;9:e2017010.","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"559_CR10","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","volume":"115","author":"E M\u00f6ssner","year":"2010","unstructured":"M\u00f6ssner E, Br\u00fcnker P, Moser S, P\u00fcntener U, Schmidt C, Herter S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010;115:4393\u2013402.","journal-title":"Blood"},{"key":"559_CR11","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1158\/1535-7163.MCT-12-1182","volume":"12","author":"S Herter","year":"2013","unstructured":"Herter S, Herting F, Mundigl O, Waldhauer I, Weinzierl T, Fauti T, et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther. 2013;12:2031\u201342.","journal-title":"Mol Cancer Ther"},{"key":"559_CR12","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","volume":"377","author":"R Marcus","year":"2017","unstructured":"Marcus R, Davies A, Kiyoshi A, Klapper W, Opat S, Owen C, et al. Obinutuumab for the first-line treatment of follicular lymphoma. New Engl J Med. 2017;377:1331\u201344.","journal-title":"New Engl J Med"},{"key":"559_CR13","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","volume":"370","author":"V Goede","year":"2014","unstructured":"Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, et al. Obinutuzumab plus chloarambucil In patients with CLLL and coexisting conditions. N Engl J Med. 2014;370:1101\u201310.","journal-title":"N Engl J Med"},{"key":"559_CR14","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S1470-2045(16)30097-3","volume":"17","author":"LH Sehn","year":"2016","unstructured":"Sehn LH, Chua N, Mayer J, Dueck G, Trn\u011bn\u00fd M, Bouabdallah K, et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol. 2016;17:1081\u201393.","journal-title":"Lancet Oncol"},{"key":"559_CR15","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059\u201368.","journal-title":"J Clin Oncol"},{"key":"559_CR16","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1200\/JCO.2017.76.3656","volume":"36","author":"BD Cheson","year":"2018","unstructured":"Cheson BD, Chua N, Mayer J, Dueck G, Trn\u011bn\u00fd M, Bouabdallah K, et al. Overall survival benefit in patients with rituximab-refractory indolent non-Hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study. J Clin Oncol. 2018;36:2259\u201366.","journal-title":"J Clin Oncol"},{"key":"559_CR17","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1038\/sj.leu.2403202","volume":"17","author":"JJ van Dongen","year":"2003","unstructured":"van Dongen JJ, Langerak AW, Br\u00fcggemann M, Evans PA, Hummel M, Lavender FL, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 concerted action BMH4-CT98-3936. Leukemia. 2003;17:2257\u2013317.","journal-title":"Leukemia"},{"key":"559_CR18","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/978-1-62703-269-8_10","volume":"971","author":"C Pott","year":"2013","unstructured":"Pott C, Br\u00fcggemann M, Ritgen M, van der Velden VH, van Dongen JJ, Kneba M. MRD detection in B-cell non-Hodgkin lymphomas using Ig gene rearrangements and chromosomal translocations as targets for real-time quantitative PCR. Methods Mol Biol. 2013;971:175\u2013200.","journal-title":"Methods Mol Biol"},{"key":"559_CR19","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/sj.leu.2404586","volume":"21","author":"VH van der Velden","year":"2007","unstructured":"van der Velden VH, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER, et al. Analysis of minimal residual disease by Ig\/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia. 2007;21:604\u201311.","journal-title":"Leukemia"},{"key":"559_CR20","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/j.1365-2141.2012.09161.x","volume":"158","author":"E Gimenez","year":"2012","unstructured":"Gimenez E, Chauvet M, Rabin L, Puteaud I, Duley S, Hamaidia S, et al. Cloned IGH VDJ targets as tools for personalized minimal residual disease monitoring in mature lymphoid malignancies; a feasibility study in mantle cell lymphoma by the Groupe Ouest Est d\u2019Etude des Leuc\u00e9mies et Autres Maladies du Sang. Br J Haematol. 2012;158:186\u201397.","journal-title":"Br J Haematol"},{"key":"559_CR21","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1038\/sj.leu.2400801","volume":"11","author":"C Voena","year":"1997","unstructured":"Voena C, Ladetto M, Astolfi M, Provan D, Gribben JG, Boccadoro M, et al. A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors. Leukemia. 1997;11:1793\u20138.","journal-title":"Leukemia"},{"key":"559_CR22","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/S0301-472X(03)00191-7","volume":"31","author":"M Ladetto","year":"2003","unstructured":"Ladetto M, Mantoan B, Ricca I, Astolfi M, Drandi D, Compagno M, et al. Recurrence of Bcl-2\/IgH polymerase chain reaction positivity following a prolonged molecular remission can be unrelated to the original follicular lymphoma clone. Exp Hematol. 2003;31:784\u2013748.","journal-title":"Exp Hematol"},{"key":"559_CR23","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1182\/blood-2015-03-630012","volume":"126","author":"F Zohren","year":"2015","unstructured":"Zohren F, Bruns I, Pechtel S, Schroeder T, Fenk R, Czibere A, et al. Prognostic value of circulating Bcl-2\/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy. Blood. 2015;126:1407\u201314.","journal-title":"Blood"},{"key":"559_CR24","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1182\/blood.V128.22.613.613","volume":"128","author":"C Pott","year":"2016","unstructured":"Pott C, Hoster E, Kehden B, Unterhalt M, Herold M, van der Jagt RH, et al. Minimal residual disease in patients with follicular lymphoma treated with obinutuzumab or rituximab as first-line induction immunochemotherapy and maintenance in the phase 3 GALLIUM study. Blood. 2016;128:613.","journal-title":"Blood"},{"key":"559_CR25","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.1182\/blood-2007-10-116749","volume":"111","author":"M Ladetto","year":"2008","unstructured":"Ladetto M, De Marco F, Benedetti F, Vitolo U, Patti C, Rambaldi A, et al. Prospective, multicenter randomized GITMO\/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood. 2008;111:4004\u201313.","journal-title":"Blood"},{"key":"559_CR26","doi-asserted-by":"publisher","first-page":"140","DOI":"10.5581\/1516-8484.20110035","volume":"33","author":"CA Buchpiguel","year":"2011","unstructured":"Buchpiguel CA. Current status of PET\/CT in the diagnosis and follow-up of lymphomas. Rev Bras Hematol Hemoter. 2011;33:140\u20137.","journal-title":"Rev Bras Hematol Hemoter"},{"key":"559_CR27","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1200\/JCO.2016.67.1305","volume":"34","author":"G Kovacs","year":"2016","unstructured":"Kovacs G, Robrecht S, Fink AM, Bahlo J, Cramer P, von Tresckow J, et al. Minimal residual disease assessment improves prediction of outcome in patients with chronic lymphocytic leukemia (CLL) who achieve partial response: comprehensive analysis of two phase III studies of the German CLL Study Group. J Clin Oncol. 2016;34:3758\u201365.","journal-title":"J Clin Oncol"},{"key":"559_CR28","doi-asserted-by":"publisher","first-page":"3679","DOI":"10.1182\/blood-2015-03-635169","volume":"125","author":"DM Kurtz","year":"2015","unstructured":"Kurtz DM, Green MR, Bratman SV, Scherer F, Liu CL, Kunder CA, et al. Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood. 2015;125:3679\u201387.","journal-title":"Blood"},{"key":"559_CR29","doi-asserted-by":"publisher","first-page":"e66","DOI":"10.3324\/haematol.2015.132811","volume":"101","author":"S Luminari","year":"2016","unstructured":"Luminari S, Galimberti S, Versari A, Biasoli I, Anastasia A, Rusconi C, et al. Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi. Haematologica. 2016;101:e66\u2013e68.","journal-title":"Haematologica"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0559-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0559-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0559-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:38:03Z","timestamp":1684618683000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-019-0559-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,28]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["559"],"URL":"https:\/\/doi.org\/10.1038\/s41375-019-0559-9","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,28]]},"assertion":[{"value":"25 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"CP reports research funding and advisory board membership for F. Hoffmann-La Roche Ltd, and advisory board membership for Janssen. DB reports research funding, advisory board membership, and consultancy fees for F. Hoffmann-La Roche Ltd, Gilead Sciences, and Janssen-Cilag. ND, GFR, CH, EWF, and KM are employees of and own stock in F. Hoffmann-La Roche Ltd. JG reports advisory board membership and research funding from Roche\/Genentech, advisory board membership for Abbvie, and speakers\u2019 fees, research funding and advisory board membership for Janssen, Acerta, Pharmacyclics, and TG Therapeutics. EH reports travel support from Roche Pharma AG. B Kahl reports advisory board membership for F. Hoffmann-La Roche Ltd. B Kehden and ENV report no conflict of interest. LHS reports consultancy fees for Roche\/Genentech, Amgen, Lundbeck, Seattle Genetics, Janssen, Celgene, Abbvie, and TG Therapeutics. BDC reports advisory board membership for Roche\/Genentech, Abbvie, and Acerta and research funding to his institution from F. Hoffmann-La Roche Ltd\/Genentech Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}